



Charles Swanton

MRCP BSc FSB PhD

Charles completed the MD PhD programme at University College London (1999) and his PhD in the laboratory of Nic Jones at the Imperial Cancer Research Fund Laboratories establishing the subversion of cell cycle control by the Kaposi's Sarcoma Herpesvirus encoded K-Cyclin (Swanton et al. Nature 1997). Charles has continued his interest in cell cycle disruption in cancer and its therapeutic applications (Swanton et al. Lancet Oncology 2004). He was made a Member of the Royal College of Physicians in 2002 and Fellow of the Society of Biologists in 2008. Charles was awarded a Cancer Research UK (CR-UK) clinician scientist fellowship in 2004 at the CR-UK London Research Institute with Prof Julian Downward, establishing multi-drug sensitivity mechanisms associated with common cytotoxics used in oncological practice (Swanton et al. Cancer Cell 2007) where he identified that regulators of mitotic arrest and ceramide metabolism were important determinants of taxane response and preliminary evidence demonstrating the association of chromosomal instability with taxane resistance in vivo (Swanton et al PNAS 2009). Charles was appointed CR-UK/MRC Group leader of the Translational Cancer Therapeutics Laboratory at the CR-UK London Research Institute and consultant medical oncologist at the Royal Marsden Hospital in the Breast and Drug Development Units in 2008 where he is aiming to better direct novel therapeutics to patients with specific breast cancer molecular subtypes within clinical trials.